Immunodermatology News

A new antibody injection for the treatment of moderate to severe plaque psoriasis met all primary and key secondary endpoints in a phase 3 Chinese study, Innovent Biologics announced in a release.

Skin disease manifestations in systemic lupus erythematosus do not have an impact on disease severity, according to a study.

Immunotherapy is a life-saving treatment for melanoma, but not all individuals have access to this treatment, according to a study.

DESTIN, Fla. — Although the strongest predictor of malignancy in dermatomyositis is age, all adult patients should undergo cancer screening, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

SB17 was clinically biosimilar to ustekinumab for the treatment of moderate to severe psoriasis, according to a study.

AbbVie reported a worldwide net revenue of $12.31 billion in the first quarter of 2024 despite Humira sales dropping due to biosimilar competition, according to a company press release.

Healio has compiled April’s most-read news in dermatology.

Incyte and Escient Pharmaceuticals have entered a definitive agreement under which Incyte will acquire Escient for $750 million, the companies announced in a press release.

Healio has compiled March’s most-read news in dermatology.

Patients with autoimmune blistering disorders had elevated cardiovascular risks, including for atherosclerotic cardiovascular disease, heart failure, arrhythmia, venous thromboembolism and death, according to a study.